Equities

SANION

SE0005794617

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 01:46:29 18/07/2024 pm IST			5-day change	1st Jan Change
3.24 ^SEK	-1.82%		-7.25%	-20.20%

13/06	Transcript : Saniona AB - Special Call
29/05	Saniona AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

BioStock: Saniona and Cephagenix comment on their joint migraine programme

January 26, 2023 at 12:47 pm IST

Last week, Danish biotech company Saniona announced the successful preclinical in vivo validation for a migraine treatment in the Cephagenix joint venture programme. BioStock reached out to Professor Jes Olesen, CEO of Cephagenix and Palle Christophersen, Executive Vice President, Research, Saniona, to learn more about the collaboration and the recent development milstone.

Read the interview with Jes Olesen and Palle Christophersen at biostock.se:

Saniona and Cephagenix comment on their joint migraine programme - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

https://news.cision.com/saniona/r/biostock--saniona-and-cephagenix-comment-on-their-joint-migraine-programme,c3703271

Latest news about SANA AB

Transcript : Saniona AB - Special Call	13/06
Saniona AB Reports Earnings Results for the First Quarter Ended March 31, 2024	29/05	CI
Terna in first quarter increases profit and revenues by double digits	08/05	AN
Saniona AB Reports Progress on Pipeline and Other Activities	07/05	CI
Imprendiroma, indicators increase to triple digits in 2023	30/04	AN
BasicNet, revenues fall in first quarter; Ebitda down double digits	30/04	AN
Digital Value in 2023 increases revenues by 20 percent; up profit	30/04	AN
Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows	01/03	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	01/03	MT
Sana Biotechnology Q4 Non-GAAP Net Loss Narrows; Cash, Cash Equivalents Decline	01/03	MT
Saniona AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02	CI
Saniona AB Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
Up slightly, rips up Campari, cues up Edison, down Technogym	27/02	RE
Israeli missile attack hits high-security district in Syrian capital	21/02	RE
Saniona AB Announces Preliminary and Unaudited Revenue Results for the Fourth Quarter and Full Year 2023	17/01	CI
Saniona Announces the Selection of Its Proprietary GABAA A5 Negative Allosteric Modulator Lead Compound, San2465	02/01	CI
Saniona AB Strengthens Epilepsy Pipeline with Selection of SAN2355 as Clinical Candidate	27/12	CI
Saniona Extends Schizophrenia Treatment Research Collaboration with Boehringer Ingelheim	18/12	MT
Saniona and Boehringer Ingelheim Extend Research Term with Up to Two Years	18/12	CI
Saniona AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	30/11	CI
Saniona AB Announces Composition of Nomination Committee	29/11	CI
Saniona Promotes Kv7 Epilepsy Compound to Candidate Selection Phase	21/11	CI
Saniona Announces Positive Preclinical Data on Saniona's SAN711 in Epilepsy Presented at SfN	27/23/27	CI
Saniona AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	31/23/31	CI
Saniona and Formue Nord Fokus A/S Agreed to Change the Terms of the Loan Agreement of June 30, 2021	14/23/14	CI

Chart SANA AB

Duration

Period

More charts

Company Profile

Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

Sector

Biotechnology & Medical Research

Calendar

29/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SANA AB	-20.20%	34.82M
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	117B
ARGENX SE	+22.77%	27.52B
BIONTECH SE	-18.07%	20.87B
GENMAB A/S	-14.34%	17.01B
BEIGENE, LTD.	-14.81%	16.26B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.56B
WUXI APPTEC CO., LTD.	-46.10%	15.09B
SAREPTA THERAPEUTICS, INC.	+52.34%	13.89B

Bio Therapeutic Drugs